Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ovemotide SCHEMBL29538753 | 1.00 | CALCRL (0.56) | CALCRLSLC6A2RAMP1RENNTSR2 | |
| SCHEMBL29449529 | 0.96 | CALCRL (0.56) | CALCRLSLC6A2RAMP1RENOPRD1 | |
| SCHEMBL30974436 | 0.92 | CALCRL (0.52) | CALCRLSLC6A2NTSR2NTSR1OPRD1 | |
| SCHEMBL29530922 | 0.88 | SLC6A2 (0.64) | CALCRLSLC6A2NTSR2NTSR1OPRD1 | |
| SCHEMBL31575684 | 0.86 | KDM1A (0.56) | SLC6A2NTSR2NTSR1KEAP1 | |
| SCHEMBL29531376 | 0.85 | SLC6A2 (0.72) | CALCRLSLC6A2OPRD1 | |
| SCHEMBL29530548 | 0.85 | SLC6A2 (0.72) | CALCRLSLC6A2OPRD1 | |
| SCHEMBL30792437 | 0.84 | NMUR2 (0.56) | — | |
| SCHEMBL31410876 | 0.83 | CALCRL (0.49) | CALCRLSLC6A2RAMP1NTSR2NTSR1 | |
| SCHEMBL29531383 | 0.81 | SLC6A2 (0.71) | CALCRLSLC6A2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 944 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053920-A1 | NOVEL TCRs | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2026-02-26 | — | — | US | claimed |
| EP-4565602-A1 | NOVEL TCRS | University College Cardiff Consultants Limited (GB) | 2025-06-11 | — | — | EP | claimed |
| US-20240288423-A1 | PEPTIDE EXCHANGE SYSTEM AND METHOD | MEDICAL & BIOLOGICAL LABORATORIES CO., LTD (JP) | 2024-08-29 | — | — | US | claimed |
| WO-2024092740-A1 | METHOD FOR DETECTING INTERCELLULAR INTERACTION AND USE THEREOF | 深圳华大生命科学研究院 | 2024-05-10 | — | — | WO | claimed |
| WO-2024028587-A1 | NOVEL TCRS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2024-02-08 | — | — | WO | claimed |
| WO-2023019583-A1 | METHOD FOR DETECTING AND SORTING ANTIGEN-SPECIFIC T-CELL RECEPTOR WITH HIGH THROUGHPUT | 深圳华大生命科学研究院 | 2023-02-23 | — | — | WO | claimed |
| CN-115429875-A | Pancreatic cancer targeted exosome vaccine for improving immunosuppressive microenvironment | 复旦大学 | 2022-12-06 | — | — | CN | claimed |
| CN-115414494-A | Polypeptide nano vaccine and preparation method and application thereof | 南京中医药大学 | 2022-12-02 | — | — | CN | claimed |
| CN-114517211-A | Immune cell culture and specific load activation method based on liposome-delivered mRNA | 苏州班凯基因科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| EP-4748400-A1 | CONJUGATE FOR ANTIGEN DELIVERY AND USE THEREOF | LG Chem, Ltd. (KR) | 2026-05-27 | — | — | EP | disclosed |
| US-12630606-B2 | Peptide deficient-MHC class I/chaperone compositions and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260116950-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260116918-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260110113-A1 | RABBIT-DERIVED ANTIGEN BINDING PROTEIN NUCLEIC ACID LIBRARIES AND METHODS OF MAKING THE SAME | CDR LIFE AG (CH) | 2026-04-23 | — | — | US | disclosed |
| US-20220056103-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-24 | — | — | US | disclosed |
| CN-107912043-B | Novel peptides and peptide compositions for immunotherapy of esophageal and other cancers | 伊玛提克斯生物技术有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11248035-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
| US-11248209-B2 | Mature dendritic cell compositions and methods for culturing same | COIMMUNE, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220041689-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| US-20220031839-A1 | IMMUNITY-INDUCING AGENT COMPRISING ANTIGEN PEPTIDE-ADJUVANT NUCLEOTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | THE UNIVERSITY OF KITAKYUSHU (JP) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248209-B2 | Mature dendritic cell compositions and methods for culturing same | CD40, CD40LG, CCR7 | CALCRL 190/4885SLC6A2 2293/4885RAMP1 1246/4885 |
| US-12630606-B2 | Peptide deficient-MHC class I/chaperone compositions and methods | MICA, TAP1, TAP2 | CALCRL 190/4885SLC6A2 4052/4885RAMP1 2340/4885 |
| US-20220031839-A1 | IMMUNITY-INDUCING AGENT COMPRISING ANTIGEN PEPTIDE-ADJUVANT NUCLEOTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TLR9, MYD88, TLR3 | CALCRL 1002/4885SLC6A2 4416/4885RAMP1 2163/4885 |
| US-20260053920-A1 | NOVEL TCRs | CD4, CD74, LY96 | CALCRL 331/4885SLC6A2 4803/4885RAMP1 3487/4885 |
| US-20260116918-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | HLA-DRB1, MICA, TAP2 | CALCRL 763/4885SLC6A2 110/4885RAMP1 1857/4885 |
| US-20260110113-A1 | RABBIT-DERIVED ANTIGEN BINDING PROTEIN NUCLEIC ACID LIBRARIES AND METHODS OF MAKING THE SAME | MICA, QPCTL, HLA-DRB1 | CALCRL 360/4885SLC6A2 2187/4885RAMP1 2927/4885 |
| US-20260116950-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | MICA, TAP1, TAP2 | CALCRL 68/4885SLC6A2 806/4885RAMP1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.